

Supporting Information

Palladium-Catalyzed Asymmetric Benzylic Substitution of Secondary Benzyl Carbonates with Nitrogen and Oxygen Nucleophiles

Atifah Najib, Koji Hirano,* and Masahiro Miura*

Department of Applied Chemistry, Graduate School of Engineering, Osaka University, Suita, Osaka 565-0871, Japan

Contents

| | |
|---|---------|
| Instrumentation and Chemicals | S1–S2 |
| Experimental Procedures | S3 |
| Detailed Optimization Studies | S4–S5 |
| X-Ray Analysis | S6 |
| Chiral HPLC Charts of Enantioenriched Products | S7–S27 |
| Characterization Data for Products | S28–S58 |

Instrumentation and Chemicals

^1H , ^{13}C , and ^{19}F NMR spectra were recorded at 400 MHz, 100 MHz, and 376 MHz, respectively, for CDCl_3 solutions. HRMS data were obtained by APCI using TOF. GC analysis was carried out using a silicon OV-17 column (2.6 mm i.d. x 1.5 m) or a CBP-1 capillary column (0.5 mm i.d. x 25 m). TLC analyses were performed on commercial glass plates bearing a 0.25 mm layer of Merck silica gel 60F₂₅₄. Silica gel (Wakosil C-200) was used for column chromatography. Gel permeation chromatography (GPC) was performed by LC-6AD (pump, SHIMADZU, 3.5 mL/min CHCl_3) and SPD-20A (UV detector, SHIMADZU, 254 nm) with two in-line GPC H-2001 (20 x 500 mm, particle size: 15 μm) and H-2002 columns (20 x 500 mm, particle size: 15 μm) (preparative columns, Shodex, CHCl_3 eluent) or by LC-20AR (pump, SHIMADZU, 7.5 mL/min EtOAc) and SPD-20A (UV detector, SHIMADZU, 254 nm) with two in-line YMC-GPC T2000 (20 x 600 mm, particle size: 10 μm) (preparative columns, YMC, EtOAc eluent). Unless otherwise noted, materials obtained from commercial suppliers were used as received. MeCN was dried on a Glass Contour Solvent dispensing system (Nikko Hansen & Co., Ltd.) prior to use. DMSO was freshly distilled from CaH_2 . (*R*)- and (*S*)-BINAP were purchased from Aldrich. $[\text{CpPd}(\eta^3-\text{C}_3\text{H}_5)]$ was prepared

according to the literature.¹ Starting carbonates **1**, including (*S*)-**1a**, were synthesized from the corresponding carbinols.² All reactions were carried out under nitrogen atmosphere unless otherwise noted.

¹ Tatsuno, Y.; Yoshida, T.; Otsuka, S.; Al-Salem, N.; Shaw, B. L. *Inorg. Synth.* **1990**, *28*, 342.

² (a) Braga, A. L.; Paixão, M. W.; Westermann, B.; Schneider, P. H.; Wessjohann, L. A. *J. Org. Chem.* **2008**, *73*, 2879. (b) Tabuchi, S.; Hirano, K.; Satoh, T.; Miura, M. *J. Org. Chem.* **2014**, *79*, 5401. (c) Tabuchi, S.; Hirano, K.; Miura, M. *Chem.-Eur. J.* **2015**, *21*, 16823.

Experimental Procedures

Synthesis of (*R*)-**3aa** (0.25 mmol scale; Table 1, entry 1): In a glovebox filled with nitrogen (*R*)-BINAP (7.8 mg, 0.0125 mmol), K₂CO₃ (69.1 mg, 0.5 mmol), and CpPd(η^3 -C₃H₅) (2.7 mg, 0.0125 mmol) were placed in a 20 mL two neck flask. The flask was sealed with a septum and taken out of the glovebox. MeCN (2.0 mL) was added, and the suspension was stirred for 10 min. A solution of *tert*-butyl (2-naphthyl (phenyl) methyl) carbonate (**1a**; 83.6 mg, 0.25 mmol) and *N*-methyl-*N*-tosylamide (**2a**; 55.6 mg, 0.30 mmol) in MeCN (1.0 mL) was then added to the flask, and the suspension was stirred for 6 h at 60 °C. The resulting mixture was quenched with water and then extracted three times with ethyl acetate. The combined organic layer was dried over sodium sulfate. Concentration in vacuo and subsequent purification by column chromatography on silica gel with hexane/ethyl acetate (1/10 to 1/5 v/v) as an eluent gave (*R*)-*N*,4-dimethyl-*N*-(naphthalen-2-yl(phenyl)methyl)benzenesulfonamide [(*R*)-**3aa**; 79.3 mg, 0.20 mmol, 92:8 er] in 80% yield: enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic sample (Chiralcel OD-H column, 95/5 hexane/2-propanol, 0.50 mL/min, major isomer: t_R = 24.7 min, minor isomer: t_R = 29.2 min).

Synthesis of (*R*)-**3ia** (1.0 mmol scale; Scheme 3): In a glovebox filled with nitrogen (*R*)-BINAP (31.1 mg, 0.05 mmol), K₂CO₃ (276.4 mg, 2.0 mmol), *tert*-butyl (phenanthren-9-yl (phenyl) methyl) carbonate (384.5 mg, 1.0 mmol), and CpPd(η^3 -C₃H₅) (10.6 mg, 0.05 mmol) were placed in a 50 mL two neck flask. The flask was sealed with a septum and taken out of the glovebox. MeCN (10 mL) was added, and the suspension was stirred for 10 min. A solution of *N*-methyl-*N*-tosylamide (**2a**; 22.3 mg, 1.20 mmol) in MeCN (2.0 mL) was then added to the flask, and the suspension was stirred for 6 h at 60 °C. The resulting mixture was quenched with water and then extracted three times with ethyl acetate. The combined organic layer was dried over sodium sulfate. Concentration in vacuo and subsequent purification by column chromatography on silica gel with hexane/ethyl acetate (1/5 v/v) as an eluent gave (*R*)-*N*,4-dimethyl-*N*-(phenanthren-9-yl(phenyl)methyl)benzenesulfonamide [(*R*)-**3ia**; 421.7 mg, 0.92 mmol, 98:2 er] in 92% yield: enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic sample (Chiraldak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 27.5 min, minor isomer: t_R = 30.6 min).


Detailed Optimization Studies

Table S1. Optimization Studies^[a]

| entry | chiral ligand | base | solvent | conditions | yield (%), ^[b] er ^[c] |
|-----------|--------------------------------|------------------------------------|-------------|-------------------|---|
| 1 | (S,S)-BDPP | none | MeCN | 80 °C, 3 h | 46, 66:34 |
| 2 | (R,R)-DPPBA | none | MeCN | 80 °C, 3 h | 0, n.d. |
| 3 | (R)-BINAP | none | MeCN | 80 °C, 3 h | 77, 86:14 |
| 4 | (R)-Xyl-BINAP | none | MeCN | 80 °C, 3 h | 74, 74:26 |
| 5 | (R)-DTBM-BINAP | none | MeCN | 80 °C, 3 h | 60, 72:28 |
| 6 | (R)-H₈-BINAP | none | MeCN | 80 °C, 3 h | 70, 87:13 |
| 7 | (R)-SEGPHOS | none | MeCN | 80 °C, 3 h | trace, n.d. |
| 8 | (R)-DM-SEGPHOS | none | MeCN | 80 °C, 3 h | trace, n.d. |
| 9 | (R)-DTBM-SEGPHOS | none | MeCN | 80 °C, 3 h | 48, 84:16 |
| 10 | (R)-MeO-BIPHEP | none | MeCN | 80 °C, 3 h | 61, 79:21 |
| 11 | (R)-DTBM-MeO-BIPHEP | none | MeCN | 80 °C, 3 h | 68, 56:44 |
| 12 | (R)-BINAP | none | MeCN | 60 °C, 6 h | 45, 94:6 |
| 13 | (R)-BINAP | Na ₂ CO ₃ | MeCN | 60 °C, 6 h | 59, 91:9 |
| 14 | (R)-BINAP | K₂CO₃ | MeCN | 60 °C, 6 h | 79, 92:8 |
| 15 | (R)-BINAP | Cs ₂ CO ₃ | MeCN | 60 °C, 6 h | 65, 90:10 |
| 16 | (R)-BINAP | NaOAc | MeCN | 60 °C, 6 h | 50, 90:10 |
| 17 | (R)-BINAP | KOAc | MeCN | 60 °C, 6 h | 34, 92:8 |
| 18 | (R)-BINAP | Et ₃ N | MeCN | 60 °C, 6 h | 39, 93:7 |
| 19 | (R)-BINAP | <i>i</i> -Pr ₂ NEt | MeCN | 60 °C, 6 h | 5 (NMR), n.d. |
| 20 | (R)-BINAP | K ₂ CO ₃ | DMSO | 60 °C, 6 h | 34, 83:17 |
| 21 | (R)-BINAP | none | DMSO | 80 °C, 3 h | 37, 87:13 |
| 22 | (R)-H ₈ -BINAP | K ₂ CO ₃ | MeCN | 60 °C, 6 h | 17, 93:7 |
| 23 | (R)-BINAP | K ₂ CO ₃ | MeCN | 50 °C, 24 h | 52, 80:20 |



[a] Reaction conditions: [CpPd($\eta^3\text{-C}_3\text{H}_5$)] (0.013 mmol), ligand (0.013 mmol), base (0.50 mmol), **1a** (0.25 mmol), **2a** (0.30 mmol), MeCN (3.0 mL), N₂. [b] Isolated yields are shown. [c] The enantiomeric ratios (er) are determined by HPLC analysis on a chiral stationary phase. n.d. = not

determined.



X-Ray Analysis

The X-ray quality crystals of (*R*)-**3aa** were grown from heptane/ethyl acetate.



(*R*)-**3aa**, 92:8 er


$[\alpha]_D^{20} -7.76$ (*c* 0.50, CHCl₃)

Figure S1. ORTEP Drawing (CCDC 1536820) and Specific Rotation of (*R*)-**3aa**

Chiral HPLC Charts of Enantioenriched Products


3aa: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 0.50 mL/min, major isomer: $t_R = 24.7$ min, minor isomer: $t_R = 29.2$ min, UV detection at 250 nm, 30 °C).

rac-3aa



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 27.959 | 13714526 | 50.12 |
| 2 | 33.391 | 13648943 | 49.88 |


(R)-3aa




| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 24.684 | 15551430 | 92.41 |
| 2 | 29.230 | 1276979 | 7.59 |

3ab: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 0.50 mL/min, major isomer: $t_R = 27.7$ min, minor isomer: $t_R = 36.8$ min, UV detection at 220 nm, 30 °C).

***rac*-3ab**




(R)-3ab




3ac: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 0.50 mL/min, major isomer: $t_R = 25.4$ min, minor isomer: $t_R = 28.1$ min, UV detection at 250 nm, 30 °C).

***rac*-3ac**




(R)-3ac




3ad: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 0.50 mL/min, major isomer: $t_R = 15.8$ min, minor isomer: $t_R = 20.3$ min, UV detection at 250 nm, 30 °C).

***rac*-3ad**




(R)-3ad




3ae: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 97/3 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 19.1$ min, minor isomer: $t_R = 20.5$ min, UV detection at 210 nm, 30 °C).

***rac*-3ae**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 16.012 | 8074177 | 50.34 |
| 2 | 18.715 | 7966127 | 49.66 |


(R)-3ae



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 19.125 | 59148445 | 92.78 |
| 2 | 20.549 | 4600649 | 7.22 |


3af: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 97/3 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 23.8$ min, minor isomer: $t_R = 26.9$ min, UV detection at 270 nm, 30 °C).

***rac*-3af**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 26.758 | 1413775 | 50.36 |
| 2 | 30.474 | 1393542 | 49.64 |


(R)-3af



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|--------|--------|
| 1 | 23.809 | 741307 | 89.96 |
| 2 | 26.853 | 82759 | 10.01 |


The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 8.7$ min, minor isomer: $t_R = 12.3$ min, UV detection at 260 nm, 30 °C).

rac-3ag



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|--------|--------|
| 1 | 8.990 | 962890 | 49.84 |
| 2 | 12.629 | 968909 | 50.16 |


(R)-3ag



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 8.726 | 1415635 | 88.17 |
| 2 | 12.333 | 190016 | 11.83 |


3ba: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 99.5/0.5 *n*-hexane/2-propanol, 2.5 mL/min (60 min) then 90/10 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 79.7$ min, minor isomer: $t_R = 85.4$ min, UV detection at 228 nm, 30 °C).

***rac*-3ba**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 80.104 | 38236813 | 50.46 |
| 2 | 85.439 | 37543409 | 49.54 |


(R)-3ba




| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 79.658 | 45175852 | 89.07 |
| 2 | 85.409 | 5543172 | 10.93 |

3ca: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 21.8$ min, minor isomer: $t_R = 23.2$ min, UV detection at 220 nm, 30 °C).

rac-**3ca**




(R)-**3ca**




3da: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 35.7$ min, minor isomer: $t_R = 37.9$ min, UV detection at 230 nm, 30 °C).

rac-**3da**




(*R*)-**3da**




3ea: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 97/3 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 47.9$ min, minor isomer: $t_R = 44.1$ min, UV detection at 228.0 nm, 30 °C).

rac-3ea




(S)-3ea




3fa: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 97/3 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 20.5$ min, minor isomer: $t_R = 18.7$ min, UV detection at 220 nm, 30 °C).

rac-**3fa**




(S)-**3fa**




3ga: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 15.8$ min, minor isomer: $t_R = 18.3$ min, UV detection at 235 nm, 30 °C).

rac-**3ga**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 15.591 | 2874515 | 50.12 |
| 2 | 17.906 | 2860975 | 49.88 |


(R)-**3ga**




| Peak # | Ret. Time | Area | Area % |
|--------|-----------|----------|--------|
| 1 | 15.804 | 25047196 | 88.53 |
| 2 | 18.258 | 3245014 | 11.47 |

3ge: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 32.5$ min, minor isomer: $t_R = 36.7$ min, UV detection at 235 nm, 30 °C).

***rac*-3ge**




(R)-3ge




3ha: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 24.7$ min, minor isomer: $t_R = 19.4$ min, UV detection at 220 nm, 30 °C).

rac-**3ha**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 19.234 | 2749972 | 48.93 |
| 2 | 24.451 | 2870476 | 51.07 |


(*R*)-**3ha**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 19.361 | 950478 | 18.27 |
| 2 | 24.669 | 4251350 | 81.73 |


3ia: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 25.9$ 1min, minor isomer: $t_R = 29.2$ min, UV detection at 260 nm, 30 °C).

***rac*-3ia**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|--------|--------|
| 1 | 26.418 | 498744 | 50.08 |
| 2 | 29.453 | 497155 | 49.92 |


(R)-3ia




| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 25.930 | 3859402 | 96.46 |
| 2 | 29.172 | 141765 | 3.54 |

3ja: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 24.0$ min, minor isomer: $t_R = 20.3$ min, UV detection at 220 nm, 30 °C).

rac-**3ja**




(R)-**3ja**




3ka: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 25.0$ min, minor isomer: $t_R = 29.4$ min, UV detection at 230 nm, 30 °C).

rac-**3ka**



| Peak # | Ret. Time | Area | Area % |
|--------|-----------|--------|--------|
| 1 | 24.588 | 795838 | 50.09 |
| 2 | 28.724 | 792830 | 49.91 |


(R)-**3ka**




| Peak # | Ret. Time | Area | Area % |
|--------|-----------|---------|--------|
| 1 | 25.042 | 6146877 | 88.27 |
| 2 | 29.382 | 817012 | 11.73 |

6aa: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 7.1$ min, minor isomer: $t_R = 7.7$ min, UV detection at 235 nm, 30 °C).

rac-**6aa**




(*R*)-**6aa**




6ab: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.00 mL/min, major isomer: $t_R = 5.5$ min, minor isomer: $t_R = 6.2$ min, UV detection at 235 nm, 30 °C).

***rac*-6ab**




(R)- 6ab




6ac: The enantiomeric ratio was determined by HPLC analysis in comparison with authentic racemic material (CHIRALPAK AD-H column, 95/5 *n*-hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 9.0$ min, minor isomer: $t_R = 10.2$ min, UV detection at 235 nm, 30 °C).

***rac*-6ac**



(R)-6ac



Characterization Data for Products

¹H, ¹³C{¹H}, and ¹⁹F NMR spectra for all compounds are attached in the last part.

N,4-Dimethyl-N-(naphthalen-2-yl(phenyl)methyl)benzenesulfonamide (3aa) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 79.3 mg (79%, 92:8 er); white solid; mp 109-110 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.38 (s, 3H), 2.74 (s, 3H), 6.61 (s, 1H), 7.10-7.16 (m, 2H), 7.16-7.22 (m, 3H), 7.27-7.31 (m, 3H), 7.43 (s, 1H), 7.45-7.50 (m, 2H), 7.61-7.67 (m, 3H), 7.73 (d, *J* = 8.6 Hz, 1H), 7.78-7.83 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.49, 31.36, 64.36, 126.24, 126.27, 126.60, 127.29, 127.57, 127.71, 127.84, 128.03, 128.04, 128.44, 128.89, 129.48, 132.70, 133.06, 135.82, 136.99, 138.39, 143.16; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₅H₂₂NO₂S: 400.1355, found: 400.1366. Chiralcel OD-H column, 95/5 hexane/2-propanol, 0.50 mL/min, major isomer: t_R = 24.7 min, minor isomer: t_R = 29.2 min.

4-Methoxy-N-methyl-N-(naphthalen-2-yl(phenyl)methyl)benzenesulfonamide (3ab) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 49.1 mg (47%, 90:10 er); white solid; mp 102-104 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.73 (s, 3H), 3.81 (s, 3H), 6.61 (s, 1H), 6.84 (d, *J* = 9.0 Hz, 2H), 7.11-7.19 (m, 2H), 7.20 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.26-7.34 (m, 3H), 7.41-7.52 (m, 3H), 7.63-7.70 (m, 3H), 7.74 (d, *J* = 8.6 Hz, 1H), 7.78-7.84 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 31.34, 55.57, 64.34, 113.97(two peaks overlapped), 126.24, 126.60, 127.56, 127.70, 127.84, 128.02, 128.04, 128.44, 128.88, 129.35, 131.65, 132.69, 133.06, 135.87, 138.41, 162.67; HRMS (APCI) *m/z* (M-H)⁺ for C₂₅H₂₂NO₃S: 416.1315, found: 416.1319. Chiralcel OD-H column, 95/5 hexane/2-propanol, 0.50 mL/min, major isomer: t_R = 27.7 min, minor isomer: t_R = 36.8 min.

4-Chloro-N-methyl-N-(naphthalen-2-yl(phenyl)methyl)benzenesulfonamide (3ac) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 59.1 mg (56%, 90:10 er); oil; ¹H NMR (400 MHz, CDCl₃) δ 2.76 (s, 3H), 6.61 (s, 1H), 7.09-7.17 (m, 2H), 7.21 (dd, *J* = 8.6, 1.8 Hz, 1H), 7.28-7.26 (m, 5H), 7.43 (s, 1H), 7.45-7.52 (m, 2H), 7.61-7.70 (m, 3H), 7.76 (d, *J* = 8.6 Hz, 1H), 7.79-7.85 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 27.90, 64.60, 126.44, 127.59, 127.82, 127.91, 128.00, 128.25, 128.56, 128.65, 128.80, 129.05, 129.08, 129.23, 132.72, 133.00, 135.45, 137.96, 138.29, 138.84; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₄H₁₉ClNO₂S: 420.0820, found: 420.0819. Chiralcel OD-H column, 95/5 hexane/2-propanol, 0.50 mL/min, major isomer: t_R = 25.4 min, minor isomer: t_R = 28.1 min.

N,2,4,6-Tetramethyl-N-(naphthalen-2-yl(phenyl)methyl)benzenesulfonamide (3ad) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/80 v/v) as an eluent; 76.2 mg (71%, 91:9 er); white solid; mp 73–75 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.30 (s, 3H), 2.54 (s, 6H), 2.74 (s, 3H), 6.49 (s, 1H), 6.92 (s, 2H), 7.15–7.22 (m, 2H), 7.26–7.34 (m, 4H), 7.43–7.51 (m, 3H), 7.66–7.73 (m, 1H), 7.77 (d, *J* = 8.6 Hz, 1H), 7.79–7.85 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 27.93, 31.34, 55.58, 64.32, 113.82, 113.96, 126.25, 126.60, 127.55, 127.70, 127.83, 128.02, 128.05, 128.44, 128.88, 129.35, 129.98, 131.61, 132.68, 135.85, 138.40, 162.66; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₇H₂₆NO₂S: 428.1679, found: 428.1679. Chiralcel OD-H column, 95/5 hexane/2-propanol, 0.50 mL/min, major isomer: t_R = 15.8 min, minor isomer: t_R = 20.3 min.

N-Methyl-N-(naphthalen-2-yl(phenyl)methyl)thiophene-2-sulfonamide (3ae) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 78.0 mg (79%, 93:7 er); oil; ¹H NMR (400 MHz, CDCl₃) δ 2.80 (s, 3H), 6.62 (s, 1H), 7.00 (dd, *J* = 3.8, 5.0 Hz, 1H), 7.11–7.17 (m, 2H), 7.20 (dd, *J* = 8.6 Hz, 1.8 Hz, 1H), 7.28–7.34 (m, 3H), 7.43–7.53 (m, 5H), 7.67–7.73 (m, 1H), 7.75 (d, *J* = 8.7 Hz, 1H), 7.79–7.85 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 31.54, 64.80, 126.33, 126.35, 126.44, 127.16, 127.58, 127.80, 127.86, 128.08, 128.13, 128.49, 128.82, 131.43, 131.91, 132.75, 133.07, 135.56, 138.06, 140.59; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₂H₁₈NO₂S₂: 392.0773, found: 392.0767. Chiralcel OD-H column, 97/3 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 19.1 min, minor isomer: t_R = 20.5 min.

N-Methyl-N-(naphthalen-2-yl(phenyl)methyl)methanesulfonamide (3af) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 41.6 mg (51%, 90:10 er); brown solid; mp 116–118 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.68 (s, 3H), 2.83 (s, 3H), 6.57 (s, 1H), 7.31–7.45 (m, 6H), 7.48–7.55 (m, 2H), 7.71 (s, 1H), 7.78–7.84 (m, 1H), 7.84–7.90 (m, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 30.92, 38.29, 64.53, 126.42, 126.48 (two peaks overlapped), 127.65, 127.89, 128.08 (two peaks overlapped), 128.45, 128.74, 128.87, 132.86, 133.15, 135.45, 137.85; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₁₉H₁₈NO₂S: 324.1053, found: 324.1060. Chiralcel OD-H column, 97/3 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 23.8 min, minor isomer: t_R = 26.9 min.

4-(Naphthalen-2-yl(phenyl)methyl)morpholine (3ag) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/20 to 1/10 v/v) as an eluent; 44.7 mg (59%, 88:12 er); white solid; mp

126-128 °C; ^1H NMR (400 MHz, CDCl_3) δ 2.44 (d, $J = 4.6$ Hz, 4H), 3.73 (t, $J = 4.6$ Hz, 4H), 4.37 (s, 1H), 7.17 (tt, $J = 7.3, 1.3$ Hz, 1H), 7.26-7.30 (m, 2H), 7.42 (dtd, $J = 14.6, 6.9, 1.4$ Hz, 2H), 7.46-7.53 (m, 2H), 7.60 (dd, $J = 8.6, 1.6$ Hz, 1H), 7.71-7.82 (m, 3H), 7.84 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 52.78, 67.23, 76.83, 125.70, 125.81, 126.02, 126.67, 127.11, 127.59, 127.78, 128.01, 128.37, 128.58, 132.75, 133.47, 139.91, 142.18; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{21}\text{H}_{20}\text{NO}$: 302.1539, found: 302.1540. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_{\text{R}} = 8.7$ min, minor isomer: $t_{\text{R}} = 12.3$ min.

N-((4-Methoxyphenyl)(naphthalen-2-yl)methyl)-N,4-dimethylbenzenesulfonamide (3ba) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 86.3 mg (80%, 89:11 er); oil; ^1H NMR (400 MHz, CDCl_3) δ 2.38 (s, 3H), 2.73 (s, 3H), 3.80 (s, 3H), 6.56 (s, 1H), 6.80 (d, $J = 8.8$ Hz, 2H), 7.02 (d, $J = 8.4$ Hz, 2H), 7.15-7.22 (m, 3H), 7.40-7.52 (m, 3H), 7.59-7.68 (m, 3H), 7.73 (d, $J = 8.6$ Hz, 1H), 7.76-7.84 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.47, 31.22, 55.30, 63.86, 113.74, 126.17, 126.18, 126.46, 127.27, 127.46, 127.54, 127.98, 128.02, 129.45, 130.26, 130.34, 132.65, 133.06, 136.16, 137.05, 143.08, 159.09; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{NO}_3\text{S}$: 430.1477, found: 430.1477. Chiralpak AD-H column, 99.5/0.5 hexane/2-propanol, 2.5 mL/min (60 min) then 90/10 hexane/2-propanol, 1.0 mL/min, major isomer: $t_{\text{R}} = 79.7$ min, minor isomer: $t_{\text{R}} = 85.4$ min.

N,4-Dimethyl-N-(naphthalen-2-yl(4-trifluoromethyl)phenyl)methylbenzenesulfonamide (3ca) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 63.4 mg (54%, 84:16 er); white solid; mp 100-102 °C; ^1H NMR (400 MHz, CDCl_3) δ 2.40 (s, 3H), 2.74 (s, 3H), 6.64 (s, 1H), 7.12 (dd, $J = 8.7, 1.9$ Hz, 1H), 7.21 (d, $J = 8.0$ Hz, 2H), 7.29 (d, $J = 8.0$ Hz, 2H), 7.35 (s, 1H), 7.44-7.52 (m, 2H), 7.56 (d, $J = 8.2$ Hz, 2H), 7.61-7.66 (m, 3H), 7.75 (d, $J = 8.6$ Hz, 1H), 7.79-7.84 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.49, 31.43, 64.00, 123.87 (q, $J = 271$ Hz), 125.42 (q, $J = 3.4$ Hz), 126.44, 126.8, 126.58, 127.23, 127.61, 128.00, 128.24, 128.36, 128.91, 129.59, 129.92 (q, $J = 31.8$ Hz), 132.79, 132.98, 134.75, 136.70, 142.70, 143.49; ^{19}F NMR (376 MHz, CDCl_3) δ -62.51; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{26}\text{H}_{21}\text{F}_3\text{NO}_2\text{S}$: 468.1240, found: 468.1238. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_{\text{R}} = 21.8$ min, minor isomer: $t_{\text{R}} = 23.2$ min.

N-((4-Chlorophenyl)(naphthalen-2-yl)methyl)-N,4-dimethylbenzenesulfonamide (3da) Purified

by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 67.4 mg (63%, 87:13 er); oil; ^1H NMR (400 MHz, CDCl_3) δ 2.39 (s, 3H), 2.72 (s, 3H), 6.57 (s, 1H), 7.08 (d, J = 8.3 Hz, 2H), 7.14 (dd, J = 8.6, 1.8 Hz, 1H), 7.21 (d, J = 8.0 Hz, 2H), 7.24-7.29 (m, 2H), 7.38 (s, 1H), 7.43-7.52 (m, 2H), 7.61-7.67 (m, 3H), 7.74 (d, J = 8.5 Hz, 1H), 7.78-7.84 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.52, 31.30, 63.74, 126.39, 126.40, 126.44, 127.25, 127.58, 127.92, 128.00, 128.22, 128.63, 129.57, 130.12, 132.73, 132.99, 133.62, 135.18, 136.80, 137.03, 143.38; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{25}\text{H}_{21}\text{ClNO}_2\text{S}$: 434.0976, found: 434.0975. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: t_{R} = 35.7 min, minor isomer: t_{R} = 37.9 min, UV detection at 230 nm, 30 °C).

N-((3-Methoxyphenyl)(naphthalen-2-yl)methyl)-N,4-dimethylbenzenesulfonamide (3ea) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 89.7 mg (83%, 92:8 er); white solid; mp 98-100 °C; ^1H NMR (400 MHz, CDCl_3) δ 2.38 (s, 3H), 2.75 (s, 3H), 3.69 (s, 3H), 6.57 (s, 1H), 6.63 (s, 1H), 6.69 (dt, J = 7.6, 0.8 Hz, 1H), 6.82 (dd, J = 8.1, 2.4 Hz, 1H), 7.15-7.24 (m, 4H), 7.42-7.51 (m, 3H), 7.62-7.67 (m, 3H), 7.73 (d, J = 8.6 Hz, 1H), 7.78-7.82 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.49, 31.46, 55.17, 64.30, 113.20, 114.45, 121.27, 126.22, 126.26, 126.60, 127.28, 127.56, 127.80, 128.03, 128.05, 129.41, 129.49, 132.70, 133.04, 135.72, 136.95, 140.01, 143.17, 159.66; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{NO}_3\text{S}$: 430.1477, found: 430.1470. Chiralpak AD-H column, 97/3 hexane/2-propanol, 1.0 mL/min, major isomer: t_{R} = 47.9 min, minor isomer: t_{R} = 44.1 min.

N,4-Dimethyl-N-(naphthalen-2-yl(*o*-tolyl)methyl)benzenesulfonamide (3fa) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 74.1 mg (71%, 96:4 er); oil; ^1H NMR (400 MHz, CDCl_3) δ 2.28 (s, 3H), 2.36 (s, 3H), 2.72 (s, 3H), 6.73 (s, 1H), 6.95 (d, J = 7.6 Hz, 1H), 7.04-7.18 (m, 4H), 7.16 (s, 1H), 7.18-7.22 (m, 2H), 7.38-7.48 (m, 2H), 7.50 (dd, J = 7.2, 1.7 Hz, 1H), 7.55 (dd, J = 6.6, 1.8 Hz, 2H), 7.69 (d, J = 8.6 Hz, 1H), 7.78 (dd, J = 7.3, 1.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 19.78, 21.47, 32.30, 62.01, 125.89, 126.20, 126.22, 126.61, 127.33, 127.43, 127.57, 127.76, 127.95, 128.26, 128.46, 129.34, 130.93, 132.64, 133.03, 136.07, 136.76, 136.98, 137.32, 143.06; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{26}\text{H}_{24}\text{NO}_2\text{S}$: 414.1528, found: 414.1521. Chiralpak AD-H column, 97/3 hexane/2-propanol, 1.0 mL/min, major isomer: t_{R} = 20.5 min, minor isomer: t_{R} = 18.7 min.

N-((6-Methoxynaphthalen-2-yl)(phenyl)methyl)-N,4-dimethylbenzenesulfonamide (3ga) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 68.2 mg (63%, 89:11 er); oil; ¹H NMR (400 MHz, CDCl₃) δ 2.37 (s, 3H), 2.72 (s, 3H), 3.90 (s, 3H), 6.58 (s, 1H), 7.06-7.20 (m, 7H), 7.25-7.30 (m, 3H), 7.33 (s, 1H), 7.52 (d, *J* = 8.6 Hz, 1H), 7.63 (d, *J* = 8.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 21.50, 31.30, 55.36, 64.29, 105.55, 119.02, 126.88, 127.21, 127.29, 127.62, 127.76, 128.40, 128.47, 128.79, 129.46, 129.50, 133.42, 133.88, 137.03, 138.55, 143.10, 157.99; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₆H₂₄NO₃S: 430.1471, found: 430.1475. Chiralcel OD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 15.8 min, minor isomer: t_R = 18.3 min.

N-((6-Methoxynaphthalen-2-yl)(phenyl)methyl)-N-methylthiophene-2-sulfonamide (3ge) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 67.5 mg (62%, 92:8 er); oil; ¹H NMR (400 MHz, CDCl₃) δ 2.79 (s, 3H), 3.91 (s, 3H), 6.58 (s, 1H), 6.99 (dd, *J* = 3.8, 5.0 Hz, 1H), 7.07-7.19 (m, 5H), 7.26-7.32 (m, 3H), 7.40 (s, 1H), 7.44-7.50 (m, 2H), 7.58 (d, *J* = 8.8 Hz, 1H), 7.64 (d, *J* = 8.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 31.47, 55.35, 64.75, 105.58, 119.10, 126.94, 127.05, 127.12, 127.58, 127.74, 128.44, 128.50, 128.72, 129.54, 131.35, 131.85, 133.15, 133.95, 138.24, 140.68, 158.07; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₃H₂₀NO₃S₂: 422.0879, found: 422.0872. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 32.5 min, minor isomer: t_R = 36.7 min.

N,4-Dimethyl-N-(naphthalen-1-yl(phenyl)methyl)benzenesulfonamide (3ha) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 62.6 mg (62%, 82:18 er); white solid; mp 142-144 °C; ¹H NMR (400 MHz, CDCl₃) δ 2.38 (s, 3H), 2.69 (s, 3H), 6.96 (d, *J* = 6.8 Hz, 2H), 7.10-7.25 (m, 7H), 7.32 (t, *J* = 7.8 Hz, 1H), 7.39-7.50 (m, 2H), 7.55 (d, *J* = 8.2 Hz, 2H), 7.78 (d, *J* = 8.2 Hz, 1H), 7.85 (d, *J* = 7.5 Hz, 1H), 8.02 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 21.51, 32.30, 61.70, 124.07, 124.92, 125.85, 126.58, 126.85, 127.07, 127.35, 127.54, 128.49, 128.73, 129.34, 129.71, 131.34, 133.88, 134.73, 136.82, 139.20, 143.02; HRMS (APCI) *m/z* (M-H)⁺ Calcd for C₂₅H₂₂NO₂S: 400.1366, found: 400.1369. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: t_R = 24.7 min, minor isomer: t_R = 19.4 min

N,4-Dimethyl-N-(phenanthren-9-yl(phenyl)methyl)benzenesulfonamide (3ia) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/5 v/v) as an eluent; 113.1 mg (>99%, 96:4

er); white solid; mp 98-100 °C; ^1H NMR (400 MHz, CDCl_3) δ 2.34 (s, 3H), 2.76 (s, 3H), 6.99-7.06 (m, 2H), 7.11 (d, $J = 8.0$ Hz, 2H), 7.15 (s, 1H), 7.17-7.27 (m, 3H), 7.31 (s, 1H), 7.48-7.67 (m, 7H), 8.00 (d, $J = 8.3$ Hz, 1H), 8.65 (d, $J = 8.2$ Hz, 1H), 8.71 (d, $J = 7.8$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.46, 32.38, 62.18, 122.44, 123.11, 125.00, 126.56, 126.67, 126.97, 127.06, 127.32, 127.73, 127.93, 128.61, 128.90, 129.00, 129.37, 130.15, 130.34, 130.79, 130.96, 132.83, 136.83, 138.85, 143.08; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{29}\text{H}_{24}\text{NO}_2\text{S}$: 450.1522, found: 450.1523 Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 25.9$ min, minor isomer: $t_R = 29.2$ min.

N,4-Dimethyl-N-(1-(naphthalen-2-yl)ethyl)benzenesulfonamide (3ja) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 40.0 mg (47%, 52:48 er); white solid; mp 121-123 °C; ^1H NMR (400 MHz, CDCl_3) δ 1.39 (d, $J = 7.0$ Hz, 3H), 2.44 (s, 3H), 2.58 (s, 3H), 5.43 (q, $J = 7.0$ Hz, 1H), 7.32 (d, $J = 8.0$ Hz, 2H), 7.43-7.51 (m, 3H), 7.64 (s, 1H), 7.72-7.84 (m, 5H); ^{13}C NMR (100 MHz, CDCl_3) 15.04, 21.57, 38.46, 54.90, 125.54, 126.08, 126.15, 126.20, 127.17, 127.58, 127.99, 128.24, 129.77, 132.74, 133.01, 137.23, 137.41, 143.21; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_2\text{S}$: 338.1209, found: 338.1207. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 24.0$ min, minor isomer: $t_R = 20.3$ min.

N-(Benzo[b]thiophen-2-yl(phenyl)methyl)-N,4-dimethylbenzenesulfonamide (3ka) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 v/v) as an eluent followed by GPC with ethyl acetate; 34.9 mg (34%, 88:12 er); white solid; mp 143-145 °C; ^1H NMR (400 MHz, CDCl_3) δ 2.36 (s, 3H), 2.79 (s, 3H), 6.71 (s, 1H), 6.94 (s, 1H), 7.17 (d, $J = 8.0$ Hz, 2H), 7.27-7.35 (m, 7H), 7.60-7.67 (m, 3H), 7.71-7.75 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.50, 31.04, 61.04, 122.19, 123.56, 124.39, 124.52, 124.65, 127.39, 128.26, 128.51, 128.58, 129.43, 136.30, 137.48, 139.13, 140.00, 143.06, 143.33; HRMS (APCI) m/z (M-H) $^+$ Calcd for $\text{C}_{23}\text{H}_{20}\text{NO}_2\text{S}_2$: 406.0930, found: 406.0928. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 25.0$ min, minor isomer: $t_R = 29.4$ min.

N-(2-Benzylbenzo[b]thiophen-3-yl)-N,4-dimethylbenzenesulfonamide (3ka') Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 v/v) as an eluent followed by GPC with ethyl acetate; 21.7 mg (21%); oil; ^1H NMR (400 MHz, CDCl_3) δ 2.44 (s, 3H), 3.22 (s, 3H), 4.18 (d, $J = 16$ Hz, 1H), 4.31 (d, $J = 16$ Hz, 1H), 6.80 (d, $J = 8.0$ Hz, 1H), 7.60 (ddd, $J = 8.1, 7.2, 1.0$ Hz, 1H), 7.20

(ddd, $J = 8.1, 7.2, 1.0$ Hz, 1H), 7.22-7.36 (m, 7H), 7.66 (t, $J = 8.1$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.59, 34.19, 37.72, 121.26, 122.74, 124.01, 124.14, 126.79, 127.66, 128.60, 128.97, 129.27, 129.71, 135.62, 136.72, 136.75, 139.11, 143.70, 145.49; HRMS (APCI) m/z ($\text{M}+\text{H})^+$ Calcd for $\text{C}_{23}\text{H}_{22}\text{NO}_2\text{S}_2$: 408.1086, found: 408.1087.


2-(Phenoxy(phenyl)methyl)naphthalene (6aa) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/10 to 1/5 v/v) as an eluent; 64.1 mg (83%, 86:14 er); white solid; mp 92-94 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.36 (s, 1H), 6.89 (tt, $J = 7.3, 1.0$ Hz, 1H), 6.95-7.03 (m, 2H), 7.16-7.27 (m, 3H), 7.27-7.36 (m, 2H), 7.38-7.49 (m, 4H), 7.52 (dd, $J = 8.6, 1.7$ Hz, 1H), 7.73-7.83 (m, 3H), 7.87 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 81.96, 116.27, 121.15, 124.93, 125.80, 126.17, 126.30, 127.13, 127.78, 127.89, 128.18, 128.63, 128.70, 129.48, 133.02, 133.31, 138.77, 141.24, 158.23; HRMS (APCI) m/z ($\text{M}-\text{H})^+$ Calcd for $\text{C}_{23}\text{H}_{17}\text{O}$: 309.1274, found: 309.1274. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_{\text{R}} = 7.1$ min, minor isomer: $t_{\text{R}} = 7.7$ min.

2-((4-(*tert*-Butyl)phenoxy)(phenyl)methyl)naphthalene (6ab) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/150 v/v) as an eluent followed by GPC with chloroform; 67.8 mg (74%, 88:12 er); white solid; mp 110-112 °C; ^1H NMR (400 MHz, CDCl_3) δ 1.24 (s, 9H), 6.33 (s, 1H), 6.90-6.96 (m, 2H), 7.19-7.29 (m, 3H), 7.30-7.37 (m, 2H), 7.40-7.48 (m, 4H), 7.52 (dd, $J = 8.6, 1.6$ Hz, 1H), 7.76-7.84 (m, 3H), 7.87 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 31.54, 34.11, 81.97, 115.54, 124.99, 125.78, 126.10, 126.25 (two peaks overlapped), 127.14, 127.75, 127.81, 128.17, 128.57, 128.65, 132.98, 133.30, 138.95, 141.42, 143.67, 156.05; HRMS (APCI) m/z ($\text{M}-\text{H})^+$ Calcd for $\text{C}_{27}\text{H}_{25}\text{O}$: 365.1900, found: 365.1899. Chiralpak AD-H column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_{\text{R}} = 5.5$ min, minor isomer: $t_{\text{R}} = 6.2$ min.


2-(Naphthalen-2-yl(phenyl)methoxy)naphthalene (6ac) Purified by column chromatography on silica gel with ethyl acetate/hexane (1/150 v/v) as an eluent followed by GPC with chloroform; 74.8 mg (83%, 91:9 er); white solid; mp 129–130 °C; ^1H NMR (400 MHz, CDCl_3) δ 6.53 (s, 1H), 7.18 (d, $J = 2.4$ Hz, 1H), 7.25-7.34 (m, 3H), 7.34-7.38 (m, 3H), 7.42-7.50 (m, 2H), 7.49-7.52 (m, 2H), 7.55-7.61 (m, 2H), 7.70-7.77 (m, 2H), 7.78-7.87 (m, 3H), 7.94 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) 81.35, 109.55, 119.47, 123.78, 124.83, 125.74, 126.13, 126.25 (two peaks overlapped), 126.89, 127.09, 127.57, 127.72, 127.90, 128.13, 128.61, 128.69, 129.07, 129.43, 132.98, 133.27, 134.34, 138.54, 141.05, 155.96; HRMS (APCI) m/z ($\text{M}-\text{H})^+$ Calcd for $\text{C}_{27}\text{H}_{19}\text{O}$: 359.1430, found: 359.1429. Chiralpak AD-H

column, 95/5 hexane/2-propanol, 1.0 mL/min, major isomer: $t_R = 9.0$ min, minor isomer: $t_R = 10.2$ min.


[¹H and ¹³C NMR Spectra of **3aa**]




[¹H and ¹³C NMR Spectra of 3ab]




[^1H and ^{13}C NMR Spectra of **3ac**]




[^1H and ^{13}C NMR Spectra of **3ad**]




[^1H and ^{13}C NMR Spectra of **3ae**]




[¹H and ¹³C NMR Spectra of 3af]




[^1H and ^{13}C NMR Spectra of **3ag**]




[¹H and ¹³C NMR Spectra of **3ba**]




[^1H , ^{13}C , and ^{19}F NMR Spectra of **3ca**]







[¹H and ¹³C NMR Spectra of **3da**]




[¹H and ¹³C NMR Spectra of **3ea**]




[^1H and ^{13}C NMR Spectra of **3fa**]




[¹H and ¹³C NMR Spectra of 3ga]




[¹H and ¹³C NMR Spectra of 3ge]




[¹H and ¹³C NMR Spectra of **3ha**]




[¹H and ¹³C NMR Spectra of **3ia**]




[¹H and ¹³C NMR Spectra of **3ja**]




[¹H and ¹³C NMR Spectra of **3ka**]




[¹H and ¹³C NMR Spectra of 3ka']



[¹H and ¹³C NMR Spectra of **6aa**]



[¹H and ¹³C NMR Spectra of **6ab**]



[¹H, ¹³C, and ¹⁹F NMR Spectra of **6ac**]

